Sort   by:  
 Page size 
Lung cancer remains the most common cause of cancer deaths worldwide, yet there is currently a lack of diagnostic noninvasive biomarkers that could guide treatment decisions. Small molecules (<1500 Da) were measured in urine collected from 469 lung cancer patients and 536 population controls using u...
2014-05-06 | MTBLS28 | MetaboLights
Early diagnosis of acute community-acquired pneumonia (CAP) is important in patient triage and treatment decisions. To identify biomarkers that distinguish patients with CAP from non-CAP controls, we conducted an untargeted global metabolome analysis for plasma samples from142 patients with CAP (CAP...
2016-08-11 | MTBLS354 | MetaboLights

Background: Amanita poisoning causes 90-95% of global mushroom-related deaths, yet early prognostic biomarkers for Amanita poisoning are lacking.

Methods: 33 patients with Amanita poisoning were recruited and categorized into survival and death group. Multi...

2025-11-27 | MTBLS13397 | MetaboLights
A growing body of evidence suggests interplay between the gut microbiota and the pathogenesis of nonalcoholic fatty liver disease (NAFLD). However, the role of the gut microbiome in early detection of NAFLD is unclear. Prospective studies are necessary for identifying reliable, microbiome markers fo...
2022-07-11 | MTBLS2615 | MetaboLights

In our investigation, we examined biochemical parameters and identified hydroxybutyrate dehydrogenase (HBDH) as a significant predictor for diffuse large B-cell lymphoma (DLBCL) patients. A group of 100 patients was used to explore potential biomarkers related to progression-free survival (PFS). ...

2024-09-02 | MTBLS10446 | MetaboLights

Sepsis is a life-threatening syndrome requiring aggressive management, and novel noninvasive biomarkers to enable risk stratification of sepsis with high confidence and to predict the sepsis-related outcomes are urgently needed. 

A mass spectrometry–based quantitative method was used t...

2026-05-24 | MTBLS14567 | MetaboLights

Cross-talk among downstream regulatory networks of genome mutations has been the major hypothetical mechanism underlying poor prognosis and low-responsive rates for targeted therapy of pancreatic ductal adenocarcinoma (PDAC). By applying a causal inference-based mutation-upstream-of-the-metabolom...

2025-10-13 | MTBLS13111 | MetaboLights

Cross-talk among downstream regulatory networks of genome mutations has been the major hypothetical mechanism underlying poor prognosis and low-responsive rates for targeted therapy of pancreatic ductal adenocarcinoma (PDAC). By applying a causal inference-based mutation-upstream-of-the-metabolom...

2025-10-13 | MTBLS13116 | MetaboLights
Sort   by:  
 Page size